Women's Health Innovation Summit, Europe 2023

Women's Health Innovation Summit

Showcasing innovation, fuelling investment, and driving partnerships across Europe and Israel to improve the outcomes, access, and quality of healthcare for women.

Register now
Basel, Switzerland
26-27 April, 2023

Our 2023 agenda will be available shortly. Register your interest to be the first to receive it.

Why Attend

Building on the success of the Women’s Health Innovation Summit USA, we are delighted to announce we are coming back to Europe to continue the acceleration of innovation and investment in women’s health and Femtech solutions!

Globally, the European women’s health market is one of the fastest growing, with new technologies, therapeutics, devices, platforms and approaches being developed to improve women’s’ access and quality of care.

Our summit will bring together the leaders & innovators from Europe and Israel, from big pharmaceutical and medical device companies, to start-ups, Femtech, VC’s and incubator funds, to drive successful partnerships, showcase leading disruptive solutions, and to fuel the growth of these businesses and the women’s health sector.

Join the leading industry network in women’s health; our 2-day summit is guaranteed to bring value to your business strategy, connections, and growth.

Advisory Board

Author:

Gila Tolub

Partner
McKinsey & Company

Passionate about healthcare and its role in improving society, Gila advises CEOs and top teams at the leading life sciences companies on growth strategy, sustainability, Health Equity and organizational transformation. Gila also leads McKinsey's work with Healthcare Innovators in Israel supporting VC funds and CEOs in bringing healthcare innovation to market more quickly.

Gila Tolub

Partner
McKinsey & Company

Passionate about healthcare and its role in improving society, Gila advises CEOs and top teams at the leading life sciences companies on growth strategy, sustainability, Health Equity and organizational transformation. Gila also leads McKinsey's work with Healthcare Innovators in Israel supporting VC funds and CEOs in bringing healthcare innovation to market more quickly.

Author:

Jessica McCreadie

Principal
Octopus Ventures

Jess sits in the Health team, and her focus is engaging with, investing in and supporting Europe’s most promising health tech companies.

“The gap between health and life expectancy is widening and to improve quality of life in later years we need a more decentralised, preventative and personalised approach to healthcare.”

Prior to joining Octopus Ventures in June 2021, Jess led the health tech investing team at Legal & General supporting leading health innovations. She invested balance sheet capital into early-stage health tech businesses and supported scale up via board representation in her portfolio.

Earlier in her career Jess invested into and was a banker in a range of alternative asset classes including renewable energy, real estate, and Venture Capital Funds. Jess has a passion for sustainability and delivering social impact alongside economic value.

Outside of work Jess can be found enjoying London’s restaurants, cycling, running, trying out the newest fitness class on offer, or in the park running around with / after her dog.

Jessica McCreadie

Principal
Octopus Ventures

Jess sits in the Health team, and her focus is engaging with, investing in and supporting Europe’s most promising health tech companies.

“The gap between health and life expectancy is widening and to improve quality of life in later years we need a more decentralised, preventative and personalised approach to healthcare.”

Prior to joining Octopus Ventures in June 2021, Jess led the health tech investing team at Legal & General supporting leading health innovations. She invested balance sheet capital into early-stage health tech businesses and supported scale up via board representation in her portfolio.

Earlier in her career Jess invested into and was a banker in a range of alternative asset classes including renewable energy, real estate, and Venture Capital Funds. Jess has a passion for sustainability and delivering social impact alongside economic value.

Outside of work Jess can be found enjoying London’s restaurants, cycling, running, trying out the newest fitness class on offer, or in the park running around with / after her dog.

Author:

Kathrin Folkendt

Founder & CEO, Co-Founder
Femtech Insider, Perla Health

Kathrin Folkendt is the Founder & CEO at Femtech Insider, the number 1 source for all things femtech. The newsletter briefs people on deals, company and startup launches, as well as femtech and Healthtech industry insights. Alongside this, Kathrin is also the Co-Founder of PERLA Health, an evidence-based integrative approach towards changing the way that PCOS education and care are delivered.

Kathrin Folkendt

Founder & CEO, Co-Founder
Femtech Insider, Perla Health

Kathrin Folkendt is the Founder & CEO at Femtech Insider, the number 1 source for all things femtech. The newsletter briefs people on deals, company and startup launches, as well as femtech and Healthtech industry insights. Alongside this, Kathrin is also the Co-Founder of PERLA Health, an evidence-based integrative approach towards changing the way that PCOS education and care are delivered.

Author:

Keren Leshem, MBA

CEO
OCON Healthcare

Seasoned executive with over 20 years' experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD and financing.

Keren Leshem, MBA

CEO
OCON Healthcare

Seasoned executive with over 20 years' experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD and financing.

Author:

Priya Oberoi

Founding Partner
Goddess Gaia Ventures

Priya Oberoi is the Founding Partner at Goddess Gaia Ventures, which is building a £100 million pre-series A venture fund to invest in companies innovating in women’s health and wellness. She is also the Founder and Managing Partner at Oberoi Capital Partners Limited. She is an avid angel investor and has over 20 years’ experience in the legal and financial industry and has a degree from Oxford University.

Priya Oberoi

Founding Partner
Goddess Gaia Ventures

Priya Oberoi is the Founding Partner at Goddess Gaia Ventures, which is building a £100 million pre-series A venture fund to invest in companies innovating in women’s health and wellness. She is also the Founder and Managing Partner at Oberoi Capital Partners Limited. She is an avid angel investor and has over 20 years’ experience in the legal and financial industry and has a degree from Oxford University.

Author:

Chandra P. Leo

Partner
HBM Partners

Chandra P. Leo is a member of the private equity team at HBM Partners, a Swiss-based healthcare investment firm with approximately $1.8 billion in assets under management. He has been responsible for investments in more than 15 private biotech, medical device and diagnostics companies in the United States and Europe, in most cases as a board member or board observer. Collectively, these companies have so far generated five NASDAQ IPOs, five M&A transactions and four FDA-approved marketed products.

 

In the women’s health field, Chandra has backed and worked with companies focused on e.g. cervical cancer, endometriosis, uterine fibroids, gynecologic infections, urogynecologic conditions, infertility and preterm labor. Before becoming a venture capital investor, he served as a physician in the Dept. of OB/GYN at the University Hospital in Leipzig, Germany, and completed a postdoctoral fellowship in reproductive biology at Stanford University.

 

Chandra holds degrees as a Doctor of Medicine from the Freie Universität Berlin (Charité), a Master in Medicines Development (MAS) from the University of Basel, and an MBA with distinction from INSEAD (France/Singapore). He lives in Zurich with his wife (a gynecologist) and their two daughters.  

 

Chandra P. Leo

Partner
HBM Partners

Chandra P. Leo is a member of the private equity team at HBM Partners, a Swiss-based healthcare investment firm with approximately $1.8 billion in assets under management. He has been responsible for investments in more than 15 private biotech, medical device and diagnostics companies in the United States and Europe, in most cases as a board member or board observer. Collectively, these companies have so far generated five NASDAQ IPOs, five M&A transactions and four FDA-approved marketed products.

 

In the women’s health field, Chandra has backed and worked with companies focused on e.g. cervical cancer, endometriosis, uterine fibroids, gynecologic infections, urogynecologic conditions, infertility and preterm labor. Before becoming a venture capital investor, he served as a physician in the Dept. of OB/GYN at the University Hospital in Leipzig, Germany, and completed a postdoctoral fellowship in reproductive biology at Stanford University.

 

Chandra holds degrees as a Doctor of Medicine from the Freie Universität Berlin (Charité), a Master in Medicines Development (MAS) from the University of Basel, and an MBA with distinction from INSEAD (France/Singapore). He lives in Zurich with his wife (a gynecologist) and their two daughters.  

 

Author:

Lynae Brayboy

Chief Medical Officer
Clue

Lynae is the Chief Medical Officer at Clue, the company founded by Ida Tin who coined the term ‘femtech’. Clue’s mission is for women and people with cycles to make good choices for themselves, and live full lives not in spite of their biology, but in tune with it and was launched helloclue.com in February 2018 to help close the knowledge gap about the menstrual cycle—with information that’s accessible, serious, scientific, and empathetic.

Lynae Brayboy

Chief Medical Officer
Clue

Lynae is the Chief Medical Officer at Clue, the company founded by Ida Tin who coined the term ‘femtech’. Clue’s mission is for women and people with cycles to make good choices for themselves, and live full lives not in spite of their biology, but in tune with it and was launched helloclue.com in February 2018 to help close the knowledge gap about the menstrual cycle—with information that’s accessible, serious, scientific, and empathetic.

Author:

Marija Butkovic

Founder & CEO
Women of Wearables

Marija Butkovic

Founder & CEO
Women of Wearables

Key statistics

350+
Attendees
40+
Speakers
9+
Dedicated Networking Hours
100+
Start-ups

AUDIENCE BREAKDOWN

40%
Start Ups/ Femtech/ Entrepreneurs/ Innovation
35%
Pharma/ Medical Device & Diagnostics/Biotechs
20%
Investors/Funding Groups
5%
Non-profits/ Advocacy Groups
5%
Payors/ Providers/ Employers
5%
Service Providers

Start Ups/ Femtech/ Entrepreneurs/ Innovation

Pharma/ Medical Device & Diagnostics/Biotechs

Investors/Funding Groups

Non-profits/ Advocacy Groups

Payors/ Providers/ Employers

Service Providers

2022 Innovation Showcase

To kick-off our European summit, we’re showcasing the latest and best
innovations in women’s health across Europe and Israel.


15 innovative startups, selected by our prestigious Selection Committee
will take to the stage in a quick-fire round of presentations to highlight
a technology, device, service, or product that is driving the future of the
women’s health market.


If selected, startups will get the opportunity to present in front of 200+
potential investors and partners and be at the forefront of driving
solutions for unmet needs in all categories of women’s health.


All applications are stage agnostic and can relate to all solutions across
women’s health from ovarian cancer to fertility.

Applications Closed 

Deadline: 15th March 

Women's Health Series Past Attendees

2022 Partners

Platinum Partners

Gold Partners

Event Partner

Media Partner

2022 Speakers

 

Andrea Zitna

Principal
Speedinvest

Andrea Zitna is the Principal at Speedinvest, focusing on early-stage health investments across Europe. She is an experience operator turned investor who is particularly interested in businesses that challenge taboos. Prior to Speedinvest, Andrea was the Chief Revenue Officer at Elvie. She holds a degree in Physics from Oxford and an MBA from Harvard Business School.

Andrea Zitna

Principal
Speedinvest

Andrea Zitna

Principal
Speedinvest

Andrea Zitna is the Principal at Speedinvest, focusing on early-stage health investments across Europe. She is an experience operator turned investor who is particularly interested in businesses that challenge taboos. Prior to Speedinvest, Andrea was the Chief Revenue Officer at Elvie. She holds a degree in Physics from Oxford and an MBA from Harvard Business School.

 

Anna Butterworth

Founder & Director
Ultra Violet Agency

Anna Butterworth is a FemTech pioneer. She has been at the epicentre of the industry for over six years - before the term was even coined. Starting her career in PR she quickly found her calling in wider creative campaign strategy and moved through cause led organisations that support marginalised communities and promote their voices.

Anna Butterworth

Founder & Director
Ultra Violet Agency

Anna Butterworth

Founder & Director
Ultra Violet Agency

Anna Butterworth is a FemTech pioneer. She has been at the epicentre of the industry for over six years - before the term was even coined. Starting her career in PR she quickly found her calling in wider creative campaign strategy and moved through cause led organisations that support marginalised communities and promote their voices.

Landing at Elvie in 2015 she was the first communications hire and quickly grew the brand across 60+ territories leading the way in FemTech marketing strategy. Since branching out to create the world's first FemTech focused creative agency Ultra Violet, she has worked with global disruptors such as Thinx, Become, Doppel, Wuka, Mooncup, Womanizer, Soho House, The Eve Appeal and more.

 

Dominnique Karetsos

General Partner, CEO
Amboy Street Ventures, Healthy Pleasure Group,

Dominnique Karetsos is the CEO and Co-Founder at The Healthy Pleasure Group, a company with the goal of building a Sexual Health and Technology Economy for better education, innovation, and investment. Alongside this, Dominnique is also a General Partner at Amboy Street Ventures, the world’s first venture capital fund focused on sexual health and women’s health technology startups.

Dominnique Karetsos

General Partner, CEO
Amboy Street Ventures, Healthy Pleasure Group,

Dominnique Karetsos

General Partner, CEO
Amboy Street Ventures, Healthy Pleasure Group,

Dominnique Karetsos is the CEO and Co-Founder at The Healthy Pleasure Group, a company with the goal of building a Sexual Health and Technology Economy for better education, innovation, and investment. Alongside this, Dominnique is also a General Partner at Amboy Street Ventures, the world’s first venture capital fund focused on sexual health and women’s health technology startups.

 

Dr Mridula Pore

Co-Founder & Co-CEO
Peppy

Dr Mridula Pore is the Co-Founder and Co-CEO at Peppy. A next-generation solution that’s transforming digital healthcare, working with employers and private medical insurers to give individuals physical, mental and emotional support when they need it most. Mridula has spent her career driving innovations in healthcare to make it more accessible and affordable. Most recently she has led commercial teams in the pharmaceuticals and digital health industries. Prior to that she was an engagement manager at McKinsey & Co.

Dr Mridula Pore

Co-Founder & Co-CEO
Peppy

Dr Mridula Pore

Co-Founder & Co-CEO
Peppy

Dr Mridula Pore is the Co-Founder and Co-CEO at Peppy. A next-generation solution that’s transforming digital healthcare, working with employers and private medical insurers to give individuals physical, mental and emotional support when they need it most. Mridula has spent her career driving innovations in healthcare to make it more accessible and affordable. Most recently she has led commercial teams in the pharmaceuticals and digital health industries. Prior to that she was an engagement manager at McKinsey & Co. She has a PhD in chemical engineering from MIT and an MBA from the MIT Sloan.

 

Dr Nina Zoric

Associate
McKinsey & Company

Nina Zoric is a McKinsey consultant. She is a former practicing embryologist with scientific background and expertise in genetics and fertility. Nina established her practical knowledge in fertility by working in the fertility field before joining McKinsey. Combined with a thorough understanding of the trends and market landscape, she has a holistic view of the fertility space and patients’ needs.  

Dr Nina Zoric

Associate
McKinsey & Company

Dr Nina Zoric

Associate
McKinsey & Company

Nina Zoric is a McKinsey consultant. She is a former practicing embryologist with scientific background and expertise in genetics and fertility. Nina established her practical knowledge in fertility by working in the fertility field before joining McKinsey. Combined with a thorough understanding of the trends and market landscape, she has a holistic view of the fertility space and patients’ needs.  

 

Dr Ronell Klingman (Berstein)

Founder & Board Member
NOGAFem

Dr Ronell Klingman, a female healthcare professional, is Co-Founder of NOGAFem, a Non-for-profit Women’s Health Innovation organization promoting the inclusion of sex and gender sensitive methodologies into Women’s Healthcare technologies and services.

Dr Ronell Klingman (Berstein)

Founder & Board Member
NOGAFem

Dr Ronell Klingman (Berstein)

Founder & Board Member
NOGAFem

Dr Ronell Klingman, a female healthcare professional, is Co-Founder of NOGAFem, a Non-for-profit Women’s Health Innovation organization promoting the inclusion of sex and gender sensitive methodologies into Women’s Healthcare technologies and services.

Ronell is also CEO of Integremed cc, a strategic consulting company to international pharmaceutical companies, and LifeSciMed , a consulting company for Biotech companies in Israel. Together with Dr Michal Sela, Founder and COB, NOGAFem has built a 700+ professional community aimed at positively influencing the underserved women’s health ecosystem to create sustainable impact. We promote advocacy through our highly successful “Women’s Health Matters” Summits together with relevant educational platforms and play a central role in key Women’s Health landscape. Ronell is passionate about volunteering her time and expertise to innovators giving them the tools to match high unmet need challenges to appropriate sex- and gender-sensitive innovation. Assisting founders in creating business models that garner investor confidence and funding, will propel these innovations forward, enabling equitable access to highly personalized solutions to combat some of the most challenging health problems that women face. Partnering with key stakeholders in Europe and the US we are driving this initiative forward on a global level, establishing Israel as a key community of practice. I am able to bring my clinical, pharma and biotech experience, and in-depth knowledge of therapeutic areas and technologies, to help build women within this ecosystem.

 

Eileen Buttimer

Senior Vice President
Sagentia Innovation

Eileen Buttimer is Senior Vice President of New Business Development at Sagentia Innovation and has over 20 years’ experience exploring innovation opportunities with clients across multiple sectors including consumer health, pharma and med tech.  She is particularly passionate about driving innovation in the Women’s Health space.  Eileen is a strong professional skilled in International Business, Innovation Management, Entrepreneurship and Market Analysis.  She holds a PhD in Biochemistry and an MBA and prior to Sagentia Innovation, she has held R&D management positions in DuPont

Eileen Buttimer

Senior Vice President
Sagentia Innovation

Eileen Buttimer

Senior Vice President
Sagentia Innovation

Eileen Buttimer is Senior Vice President of New Business Development at Sagentia Innovation and has over 20 years’ experience exploring innovation opportunities with clients across multiple sectors including consumer health, pharma and med tech.  She is particularly passionate about driving innovation in the Women’s Health space.  Eileen is a strong professional skilled in International Business, Innovation Management, Entrepreneurship and Market Analysis.  She holds a PhD in Biochemistry and an MBA and prior to Sagentia Innovation, she has held R&D management positions in DuPont and Pfizer.

 

Gila Tolub

Partner
McKinsey & Company

Passionate about healthcare and its role in improving society, Gila advises CEOs and top teams at the leading life sciences companies on growth strategy, sustainability, Health Equity and organizational transformation. Gila also leads McKinsey's work with Healthcare Innovators in Israel supporting VC funds and CEOs in bringing healthcare innovation to market more quickly.

Gila Tolub

Partner
McKinsey & Company

Gila Tolub

Partner
McKinsey & Company

Passionate about healthcare and its role in improving society, Gila advises CEOs and top teams at the leading life sciences companies on growth strategy, sustainability, Health Equity and organizational transformation. Gila also leads McKinsey's work with Healthcare Innovators in Israel supporting VC funds and CEOs in bringing healthcare innovation to market more quickly.

 

Hana Besbes

Investment Manager
Heal Capital

Hana is Investment Manager with Heal Capital, a European VC with a volume of EUR 100m, investing in technology-enabled healthcare champions actively driving healthcare innovation from Seed and Series A stage. At Heal, Hana is driving investments in the areas of Mental Health, FemTech, Elderly Care, and Chronic Diseases. Hana has been an active Angel Investor, invested in 30+ startups, and is an advocate of female founders in tech.

Hana Besbes

Investment Manager
Heal Capital

Hana Besbes

Investment Manager
Heal Capital

Hana is Investment Manager with Heal Capital, a European VC with a volume of EUR 100m, investing in technology-enabled healthcare champions actively driving healthcare innovation from Seed and Series A stage. At Heal, Hana is driving investments in the areas of Mental Health, FemTech, Elderly Care, and Chronic Diseases. Hana has been an active Angel Investor, invested in 30+ startups, and is an advocate of female founders in tech. Hana is a former top-tier strategy consultant with BCG and Roland Berger with > 6 years across Europe and MENA in digital transformation / open innovation and building new industries from scratch. Hana has a technical background as Dipl.-Ing. Electrical Engineering, MSc Telecommunications.

 

Kalahn Taylor-Clark, PhD MPH

Vice President, Strategic Partnerships and Innovation
Myovant

Kalahn Taylor-Clark, PhD MPH

Vice President, Strategic Partnerships and Innovation
Myovant

Kalahn Taylor-Clark, PhD MPH

Vice President, Strategic Partnerships and Innovation
Myovant
 

Karina Vazirova

Co-Founder
Femtech Lab

Karina is the co-founder of FemTech Lab, a global platform for startups in women's health and wellness. Prior to FemTech Lab, Karina founded KV LABS, a product development agency focusing on UX Design, AI & Robotic Automation, led high-growth product teams, and launched digital products in the US, Australia, UK and Europe. Karina is also an International Chess Master. 

Karina Vazirova

Co-Founder
Femtech Lab

Karina Vazirova

Co-Founder
Femtech Lab

Karina is the co-founder of FemTech Lab, a global platform for startups in women's health and wellness. Prior to FemTech Lab, Karina founded KV LABS, a product development agency focusing on UX Design, AI & Robotic Automation, led high-growth product teams, and launched digital products in the US, Australia, UK and Europe. Karina is also an International Chess Master. 

 

Kathrin Folkendt

Founder & CEO, Co-Founder
Femtech Insider, Perla Health

Kathrin Folkendt is the Founder & CEO at Femtech Insider, the number 1 source for all things femtech. The newsletter briefs people on deals, company and startup launches, as well as femtech and Healthtech industry insights. Alongside this, Kathrin is also the Co-Founder of PERLA Health, an evidence-based integrative approach towards changing the way that PCOS education and care are delivered.

Kathrin Folkendt

Founder & CEO, Co-Founder
Femtech Insider, Perla Health

Kathrin Folkendt

Founder & CEO, Co-Founder
Femtech Insider, Perla Health

Kathrin Folkendt is the Founder & CEO at Femtech Insider, the number 1 source for all things femtech. The newsletter briefs people on deals, company and startup launches, as well as femtech and Healthtech industry insights. Alongside this, Kathrin is also the Co-Founder of PERLA Health, an evidence-based integrative approach towards changing the way that PCOS education and care are delivered.

 

Keren Leshem, MBA

CEO
OCON Healthcare

Seasoned executive with over 20 years' experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD and financing.

Keren Leshem, MBA

CEO
OCON Healthcare

Keren Leshem, MBA

CEO
OCON Healthcare

Seasoned executive with over 20 years' experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, BD and financing.

 

Lea von Bidder

Founder
AVA Women

Lea von Bidder is the CEO and Co-Founder of Ava Women, which leverages big data and artificial intelligence in women’s health. he company's initial product consists of a sophisticated sensor bracelet, an app and a powerful backend with self-learning algorithms for interpretation of hormonal changes, accurate ovulation tracking and screening of women's health issues.

Lea von Bidder

Founder
AVA Women

Lea von Bidder

Founder
AVA Women

Lea von Bidder is the CEO and Co-Founder of Ava Women, which leverages big data and artificial intelligence in women’s health. he company's initial product consists of a sophisticated sensor bracelet, an app and a powerful backend with self-learning algorithms for interpretation of hormonal changes, accurate ovulation tracking and screening of women's health issues.

 

Leon-Ariel Boston

CEO
MobileODT

Consummate CEO and entrepreneurial business leader with consistent track-record of success in the start-up, growth and leadership of high-performance MedTech companies.

In the last years, Leon has focused on women's health, creating new innovative products leveraging the latest digital technologies and artificial intelligence .

He is a regular contributor at different FemTech forums worldwide.

Leon-Ariel Boston

CEO
MobileODT

Leon-Ariel Boston

CEO
MobileODT

Consummate CEO and entrepreneurial business leader with consistent track-record of success in the start-up, growth and leadership of high-performance MedTech companies.

In the last years, Leon has focused on women's health, creating new innovative products leveraging the latest digital technologies and artificial intelligence .

He is a regular contributor at different FemTech forums worldwide.

As a CEO of MobileODT, Leon has been transforming the company into a fully encompassing digital health solution, built on the foundations of AI for cervical cancer screening. With further applications in women’s wellness and fertility under development, MobileODT is evolving as a leading Femtech company transforming lives and changing outcomes for women world-wide.

 

Lucanus Polagnoli

Founder & Managing Director
CalmStorm Ventures

Lucanus is one of Europe’s emerging managers: He is a founder and managing partner at Calm/Storm, an early-stage venture capital fund focused on digital-health and wellbeing. Before founding Calm/Storm in 2020, he was a startup operator, a CFO and a general partner of an early-stage fund (Speedinvest) – a combination not often found in venture capital.

Lucanus Polagnoli

Founder & Managing Director
CalmStorm Ventures

Lucanus Polagnoli

Founder & Managing Director
CalmStorm Ventures

Lucanus is one of Europe’s emerging managers: He is a founder and managing partner at Calm/Storm, an early-stage venture capital fund focused on digital-health and wellbeing. Before founding Calm/Storm in 2020, he was a startup operator, a CFO and a general partner of an early-stage fund (Speedinvest) – a combination not often found in venture capital.

Lucanus is passionate about helping others – especially founders – and will assist in every aspect of building your company. Investors and founders trust him, his hands-on approach and his knowledge around numbers. With more than 35 investments, he and the Calm/Storm team have demonstrated the ability to find and pick those rare cases where entrepreneurs are able to build both outstanding products and big businesses. Lucanus also has a real passion for digital solutions that improve our lives, and has most likely hit the limit of the number of apps "installable" on a phone.

In his free time, you’ll find him spending time with his wife and three children in the most liveable city in the world, Vienna, Austria, or sometimes racing sailing boats in his home turf, Lake Attersee in beautiful Salzkammergut – or as he calls it, “The Sound Of Music Land”.

 

Lynae Brayboy

Chief Medical Officer
Clue

Lynae is the Chief Medical Officer at Clue, the company founded by Ida Tin who coined the term ‘femtech’. Clue’s mission is for women and people with cycles to make good choices for themselves, and live full lives not in spite of their biology, but in tune with it and was launched helloclue.com in February 2018 to help close the knowledge gap about the menstrual cycle—with information that’s accessible, serious, scientific, and empathetic.

Lynae Brayboy

Chief Medical Officer
Clue

Lynae Brayboy

Chief Medical Officer
Clue

Lynae is the Chief Medical Officer at Clue, the company founded by Ida Tin who coined the term ‘femtech’. Clue’s mission is for women and people with cycles to make good choices for themselves, and live full lives not in spite of their biology, but in tune with it and was launched helloclue.com in February 2018 to help close the knowledge gap about the menstrual cycle—with information that’s accessible, serious, scientific, and empathetic.

 

Melis Guvensoy

Founder & Executive Director
Bold Innovates

Melis is a strategic consultant, entrepreneur and a business developer in life sciences. After finishing her bachelor in biochemistry at University of Leicester and her masters in cancer therapeutics at Queen Mary University of London, she has gathered experience in supply chain, sales and business analysis in the UK and Cyprus to understand the world of entrepreneurship and innovation from different industry perspectives. Later, she took on a business development role at Whale Bay & Co (Deloitte spin-off), a life sciences and health consultancy company in the Netherlands.

Melis Guvensoy

Founder & Executive Director
Bold Innovates

Melis Guvensoy

Founder & Executive Director
Bold Innovates

Melis is a strategic consultant, entrepreneur and a business developer in life sciences. After finishing her bachelor in biochemistry at University of Leicester and her masters in cancer therapeutics at Queen Mary University of London, she has gathered experience in supply chain, sales and business analysis in the UK and Cyprus to understand the world of entrepreneurship and innovation from different industry perspectives. Later, she took on a business development role at Whale Bay & Co (Deloitte spin-off), a life sciences and health consultancy company in the Netherlands. Afterwards, she joined a contract research organisation called OcellO BV, as a business manager, that does 3D in vitro compound screening in a physiologically relevant patient disease environment using organoids. She is also a board member in the European Institute of Innovation and Technology (EIT) Women community, and an active member in Cyprus Women's Health Research Society. In 2021, Melis founded Bold Innovates. In her role at Bold Innovates, next to managing the company, she leads the innovation development and growth strategy of client projects.

 

 

Priya Oberoi

Founding Partner
Goddess Gaia Ventures

Priya Oberoi is the Founding Partner at Goddess Gaia Ventures, which is building a £100 million pre-series A venture fund to invest in companies innovating in women’s health and wellness. She is also the Founder and Managing Partner at Oberoi Capital Partners Limited. She is an avid angel investor and has over 20 years’ experience in the legal and financial industry and has a degree from Oxford University.

Priya Oberoi

Founding Partner
Goddess Gaia Ventures

Priya Oberoi

Founding Partner
Goddess Gaia Ventures

Priya Oberoi is the Founding Partner at Goddess Gaia Ventures, which is building a £100 million pre-series A venture fund to invest in companies innovating in women’s health and wellness. She is also the Founder and Managing Partner at Oberoi Capital Partners Limited. She is an avid angel investor and has over 20 years’ experience in the legal and financial industry and has a degree from Oxford University.

 

Shardi Nahavandi

CEO
TUUNE

Shardi Nahavandi is the Co-Founder and CEO of TUUNE, a startup focusing on personalized birth control. She was inspired to start the company after being misdiagnosed with bowel cancer, eventually focusing on her own research on hormone imbalances.

Shardi Nahavandi

CEO
TUUNE

Shardi Nahavandi

CEO
TUUNE

Shardi Nahavandi is the Co-Founder and CEO of TUUNE, a startup focusing on personalized birth control. She was inspired to start the company after being misdiagnosed with bowel cancer, eventually focusing on her own research on hormone imbalances.

 

Therese Maria Liechtenstein

Principal
M Ventures

Therese Liechtenstein, PhD, is a Principal in the Biotechnology team of M Ventures. Therese joined M Ventures in 2018. She was instrumental in the creation and financing of multiple companies of M Ventures portfolio, including FoRx Therapeutics and Anavo Therapeutics. Thera actively leads investments and represents M Ventures on the board of multiple portfolio companies. Previously Therese managed strategic projects for the Healthcare business of Merck KGaA in Darmstadt, Germany.

Therese Maria Liechtenstein

Principal
M Ventures

Therese Maria Liechtenstein

Principal
M Ventures

Therese Liechtenstein, PhD, is a Principal in the Biotechnology team of M Ventures. Therese joined M Ventures in 2018. She was instrumental in the creation and financing of multiple companies of M Ventures portfolio, including FoRx Therapeutics and Anavo Therapeutics. Thera actively leads investments and represents M Ventures on the board of multiple portfolio companies. Previously Therese managed strategic projects for the Healthcare business of Merck KGaA in Darmstadt, Germany. Prior to Merck KGaA, Darmstadt, Germany, Therese was a client relationship manager in the field of wealth preservation, at Industrie- & Finanzkontor Ets. Therese comes from an academic background receiving her PhD in Immuno-Oncology from University College London, an MSc in Biomedical Sciences from the University of Amsterdam, and a BA in Biology and Business studies from New York University.

 

Frederik Madsen

CEO
Cirqle Biomedical

Frederik is co-founder and CEO at Cirqle Biomedical, a women's health company developing OUI®.

 

OUI is a first-in-class non-hormonal contraceptive that works by topically reinforcing the natural barrier properties of cervical mucus to prevent sperm cells from reaching and fertilising the egg. The novel mechanism of action has been demonstrated to provide breakthrough efficacy in pre-clinical animal studies. 

 

Frederik Madsen

CEO
Cirqle Biomedical

Frederik Madsen

CEO
Cirqle Biomedical

Frederik is co-founder and CEO at Cirqle Biomedical, a women's health company developing OUI®.

 

OUI is a first-in-class non-hormonal contraceptive that works by topically reinforcing the natural barrier properties of cervical mucus to prevent sperm cells from reaching and fertilising the egg. The novel mechanism of action has been demonstrated to provide breakthrough efficacy in pre-clinical animal studies. 

 

Cirqle has been awarded the Index Award, dubbed the Nobel Prize of the design world, and has been featured by amongst others Forbes, CNN and Wired Magazine for its pioneering work.

 

Frederik brings unique experience on the opportunities of applying human-centred innovation in women's health. He holds a MSc in Management of Innovation and Business Development from Copenhagen Business School.

 

Wendy Anderson

Partner & Co-Founder
The Case For Her

Wendy Anderson is a Co-founder and Investing Partner at The Case for Her, a philanthropic investment portfolio addressing the key women’s health issues of menstruation and female sexual health & pleasure. A graduate of Queen’s University in Ontario, Canada, Wendy spent over a decade working in the financial industry before transitioning to impact investing at Futura Foundations, which she directs together with her husband, acting as Chair of Social Initiatives since 2009.

Wendy Anderson

Partner & Co-Founder
The Case For Her

Wendy Anderson

Partner & Co-Founder
The Case For Her

Wendy Anderson is a Co-founder and Investing Partner at The Case for Her, a philanthropic investment portfolio addressing the key women’s health issues of menstruation and female sexual health & pleasure. A graduate of Queen’s University in Ontario, Canada, Wendy spent over a decade working in the financial industry before transitioning to impact investing at Futura Foundations, which she directs together with her husband, acting as Chair of Social Initiatives since 2009. Wendy chairs the Board at Be Girl, a mission-driven design company addressing menstruation, is on the Executive Board of Women Moving Millions and sits on the advisory boards of both Saral Designs and The Center for Intimacy Justice.

 

Allison Watkins-Conti

Founder/CEO
Watkins-Conti

Allison Watkins-Conti

Founder/CEO
Watkins-Conti

Allison Watkins-Conti

Founder/CEO
Watkins-Conti
 

Merle Hall

Chief Executive Officer, Founder
Kinneir Dufort, XXEquals

Merle Hall

Chief Executive Officer, Founder
Kinneir Dufort, XXEquals

Merle Hall

Chief Executive Officer, Founder
Kinneir Dufort, XXEquals
 

Elisabeth Weis

Associate Vice President, Global Marketing, Fertility
Organon

Elisabeth Weis is responsible for the development and execution of Organon's Fertility Franchise vision, purpose, and long-term strategy, including the unleashing of significant drivers of both organic and inorganic growth. Through effective partnering with senior leader counterparts in both the R&D and Manufacturing organizations, she is focused on maximizing the full potential of Organon's current fertility brands and successfully expanding into new areas through business development acquisitions and strategic partnerships in order to help build families around the world.

Elisabeth Weis

Associate Vice President, Global Marketing, Fertility
Organon

Elisabeth Weis

Associate Vice President, Global Marketing, Fertility
Organon

Elisabeth Weis is responsible for the development and execution of Organon's Fertility Franchise vision, purpose, and long-term strategy, including the unleashing of significant drivers of both organic and inorganic growth. Through effective partnering with senior leader counterparts in both the R&D and Manufacturing organizations, she is focused on maximizing the full potential of Organon's current fertility brands and successfully expanding into new areas through business development acquisitions and strategic partnerships in order to help build families around the world.

 

Maria del Pilar Diaz Gonzalez

CEO at FemTech
MAS Holdings

Pilar is a global and multi-cultural business senior executive with 20+ years of experience in the consumer goods industry. She started her career in Spain where she is originally from, and later spanning multiple geographic locations across USA, Italy, Portugal, Switzerland and Germany. She built her career with a focus on Strategy, Marketing, Innovation and Commercialization.

Maria del Pilar Diaz Gonzalez

CEO at FemTech
MAS Holdings

Maria del Pilar Diaz Gonzalez

CEO at FemTech
MAS Holdings

Pilar is a global and multi-cultural business senior executive with 20+ years of experience in the consumer goods industry. She started her career in Spain where she is originally from, and later spanning multiple geographic locations across USA, Italy, Portugal, Switzerland and Germany. She built her career with a focus on Strategy, Marketing, Innovation and Commercialization. Pilar is currently the CEO at FemTech at MAS Holdings, the largest and leading design-to-delivery apparel solutions provider in South Asia. In her own words, she is "passionate about helping shape the future of FemHealth, an industry with massive growth potential that has been long neglected. Very proud to work with people who dare to break the taboos surrounding female intimate health and wellness, and support women through the ups and downs, the glory, and the pain, of every stage in their lives

 

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon Altimari

Global Head of Oncology Advocacy to Outcomes
GSK

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

 

Sonia Ponzo

Director of Science
Flo Health

Sonia Ponzo

Director of Science
Flo Health

Sonia Ponzo

Director of Science
Flo Health
 

Yahel Halamish

Investor, Head of Investor Relations, D&I
Nina Capital

Yahel joined Nina Capital, a specialized venture capital firm investing exclusively at the intersection of healthcare and deep tech, in 2020. At Nina Capital, Yahel focuses on Women's health and hospital management investments. She is also in charge of Investors Relations and D&I in the fund, promoting an active approach to increasing diversity. Prior to joining Nina Capital, Yahel gained vast knowledge on the VC industry and Startups in different development stages by investing in Alternative Assets for a large investment house based in Tel Aviv.

Yahel Halamish

Investor, Head of Investor Relations, D&I
Nina Capital

Yahel Halamish

Investor, Head of Investor Relations, D&I
Nina Capital

Yahel joined Nina Capital, a specialized venture capital firm investing exclusively at the intersection of healthcare and deep tech, in 2020. At Nina Capital, Yahel focuses on Women's health and hospital management investments. She is also in charge of Investors Relations and D&I in the fund, promoting an active approach to increasing diversity. Prior to joining Nina Capital, Yahel gained vast knowledge on the VC industry and Startups in different development stages by investing in Alternative Assets for a large investment house based in Tel Aviv. Yahel started her career as a corporate lawyer, working for a top law firm in Israel, managing ongoing legal matters of public companies and IPOs. Yahel holds an MBA from IESE Business School, LLB and, BA in economics from the Hebrew University.

 

Stasia Obremskey

Partner
RH Capital

Before joining, Stasia served in 2018 as the first Fellow of the Tara Health Foundation. She has more than twenty-five years of experience providing financial and strategic planning consulting to organizations in the U.S. and Asia. She has joined management teams as the interim Chief Financial Officer on a short term and extended term basis to provide finance, accounting and strategic planning expertise to startups, fast growing companies and non-profit organizations. Current and past clients include 18Birdies, Posit Science, Circlepoint, West Shore Technologies and We Care Solar.

Stasia Obremskey

Partner
RH Capital

Stasia Obremskey

Partner
RH Capital

Before joining, Stasia served in 2018 as the first Fellow of the Tara Health Foundation. She has more than twenty-five years of experience providing financial and strategic planning consulting to organizations in the U.S. and Asia. She has joined management teams as the interim Chief Financial Officer on a short term and extended term basis to provide finance, accounting and strategic planning expertise to startups, fast growing companies and non-profit organizations. Current and past clients include 18Birdies, Posit Science, Circlepoint, West Shore Technologies and We Care Solar. She has lived for over 8 years in Bangkok, Thailand and Hong Kong, China. She began her consulting career as a management consultant with Bain & Company. Previously, she worked in investment banking for Morgan Stanley & Co. She holds a bachelor’s degree in Business Administration with a concentration in finance from the University of Notre Dame and an MBA from the Harvard Graduate School of Business. In addition to her consulting work, she has extensive experience as a member of several nonprofit boards where she has held a number of leadership positions.

 

Valentina Milanova

Founder & CPO
Daye

Valentina Milanova is the founder of Daye, the gynae health research and development company on a mission to close the gender pain gap and overcome historical gender biases in medical research and product innovation. After years of research and testing, Daye launched its first consumer product in 2020 - the world‘s only cramp-soothing tampon.  From the outset, Valentina has baked her core values into the DNA of the company - Daye‘s products are created by women who used to be in the prison system, and their tampons are produced in a fully carbon neutral operation.

Valentina Milanova

Founder & CPO
Daye

Valentina Milanova

Founder & CPO
Daye

Valentina Milanova is the founder of Daye, the gynae health research and development company on a mission to close the gender pain gap and overcome historical gender biases in medical research and product innovation. After years of research and testing, Daye launched its first consumer product in 2020 - the world‘s only cramp-soothing tampon.  From the outset, Valentina has baked her core values into the DNA of the company - Daye‘s products are created by women who used to be in the prison system, and their tampons are produced in a fully carbon neutral operation. Born and raised in Bulgaria, Valentina moved to the UK to attend the University of Buckingham, where she got degrees in business, economics, and law.  After considering careers in journalism and econometrics, Valentina soon found herself drawn in by the start-up world, working first at Techstars and then as a venture associate for Founders Factory. Meanwhile, she began working on her own idea for a company. After 180 pitches to investors, Valentina managed to raise £4.23 million in seed funding and in 2018, Daye started officially changing the face of female health for the better.

 

Marco Rüedi

Senior Business Coach
EFPL Innovation Park

Marco is Entrepreneur, Coach and Trainer in the Swiss Start-up ecosystem with 20+ years international experience in strategic and operational roles across the LifeScience Industry and Healthcare Management. He is also currently a mentor for the Tech4Eva program at EPFL Innovation Park.

Marco Rüedi

Senior Business Coach
EFPL Innovation Park

Marco Rüedi

Senior Business Coach
EFPL Innovation Park

Marco is Entrepreneur, Coach and Trainer in the Swiss Start-up ecosystem with 20+ years international experience in strategic and operational roles across the LifeScience Industry and Healthcare Management. He is also currently a mentor for the Tech4Eva program at EPFL Innovation Park.

He is a strong believer in well-balanced teams: motivated to challenge the status quo!
Passionate to work with the next generation of Entrepreneurs/Managers for the challenges of tomorrow. He focused on Start-up and Innovation Management, Translational medicine. His motto is “From idea to market”.

He holds a Medical Doctor from the University of Fribourg, Berne and Zurich, an Executive Masters in Medical Management from eMMM PHW Berne, and an Executive Masters in Business Administration from eMBA PHW Berne.

 

Jessica Platt

Insight Researcher
Cambridge Design Partnership

Jessica Platt

Insight Researcher
Cambridge Design Partnership

Jessica Platt

Insight Researcher
Cambridge Design Partnership
 

Kerry Briggs

Head of Medical
Kinneir Dufort

Kerry Briggs

Head of Medical
Kinneir Dufort

Kerry Briggs

Head of Medical
Kinneir Dufort
 

Jessica McCreadie

Principal
Octopus Ventures

Jess sits in the Health team, and her focus is engaging with, investing in and supporting Europe’s most promising health tech companies.

“The gap between health and life expectancy is widening and to improve quality of life in later years we need a more decentralised, preventative and personalised approach to healthcare.”

Jessica McCreadie

Principal
Octopus Ventures

Jessica McCreadie

Principal
Octopus Ventures

Jess sits in the Health team, and her focus is engaging with, investing in and supporting Europe’s most promising health tech companies.

“The gap between health and life expectancy is widening and to improve quality of life in later years we need a more decentralised, preventative and personalised approach to healthcare.”

Prior to joining Octopus Ventures in June 2021, Jess led the health tech investing team at Legal & General supporting leading health innovations. She invested balance sheet capital into early-stage health tech businesses and supported scale up via board representation in her portfolio.

Earlier in her career Jess invested into and was a banker in a range of alternative asset classes including renewable energy, real estate, and Venture Capital Funds. Jess has a passion for sustainability and delivering social impact alongside economic value.

Outside of work Jess can be found enjoying London’s restaurants, cycling, running, trying out the newest fitness class on offer, or in the park running around with / after her dog.

 

Marion McPherson

Global Therapy Area Head for Women's Healthcare
Bayer Pharmaceuticals

Marion McPherson is the Therapy Area Head for Women’s Healthcare in Bayer Pharmaceuticals. She joined Bayer in 1997 and during that time and has held a variety of commercial leadership roles in both the Pharmaceutical and Crop Science divisions in the UK and across Europe. Marion started her career in the field of Women’s Health as a nurse and midwife and is passionate about delivering innovative solutions to address the unmet medical needs of women worldwide.

Marion McPherson

Global Therapy Area Head for Women's Healthcare
Bayer Pharmaceuticals

Marion McPherson

Global Therapy Area Head for Women's Healthcare
Bayer Pharmaceuticals

Marion McPherson is the Therapy Area Head for Women’s Healthcare in Bayer Pharmaceuticals. She joined Bayer in 1997 and during that time and has held a variety of commercial leadership roles in both the Pharmaceutical and Crop Science divisions in the UK and across Europe. Marion started her career in the field of Women’s Health as a nurse and midwife and is passionate about delivering innovative solutions to address the unmet medical needs of women worldwide.

 

Kimon Angelides

Executive Chairman & CEO
FemTec Health

Kimon Angelides is the founder of six healthcare companies: FemTec Health, Vivante Health, EosHealth which became Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently acquired by Teladoc for $18.5B, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment, provider risk models, and the first remote monitoring of patients, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

 

Kimon Angelides

Executive Chairman & CEO
FemTec Health

Kimon Angelides

Executive Chairman & CEO
FemTec Health

Kimon Angelides is the founder of six healthcare companies: FemTec Health, Vivante Health, EosHealth which became Livongo (NASDAQ: LVGO) and debuted in July 2019 with a $355M IPO at a $4.4B valuation and recently acquired by Teladoc for $18.5B, DiabetesAmerica, a network of diabetes centers that pioneered bundled payment, provider risk models, and the first remote monitoring of patients, and mAbGen, a cancer biotech company that partnered with world-renowned MDAnderson Cancer Center and was acquired by Valeant Pharmaceuticals.

 

Kimon recently received the 2020 Founder of the Year Award from Rock Health, Goldman Sachs, and PacWest Bank for his contributions and work in digital medicine.  Kimon’s newest company, FemTec Health was created in 2020 to bring together all the product and services to create a total healthcare experience for women and to tackle some of the most complex health conditions using state of the art technologies. The company has taken a multidisciplinary approach using digital therapeutics, diagnostics and discovery medicine, devices, and analytics, all taken to enhance and celebrate women’s health and to break some of the taboos associated with women’s sexual wellness.   Vivante Health, that Kimon founded in 2016 after Livongo was formed to meet the needs of people who have invisible and stigmatized diseases, starting with digestive health using new advances and innovations in digital health, telemedicine, and biometric devices. 

 

Prior to his healthcare career, Kimon led strategy for Tanox, Inc., a biotech company now part of Genentech, Director of Strategic Development at St Luke’s/Texas Heart Institute, Professor and Chair of Cell Biology and Biomedical Sciences at the University of Durham in the UK building the pre-clinical services for a new medical school, Professor of Cell Biology, Neuroscience, Biochemistry, and Molecular Biophysics at Baylor College of Medicine, and Associate and Assistant Professor at the University of Florida and McGill University. Kimon was on the National Medical Board of the National Multiple Sclerosis Society, Muscular Dystrophy Association, and the National Institutes of Health. Kimon was a Research Career Development Awardee of the National Institutes of Health, a Mombusho Scholar of Japan, Distinguished Professor at INSERM/Centre National de Recherche Scientifique of France, and a Basil O’Connor Scholar from the March of Dimes Birth Defect Foundation. He has published over 100 papers and holds more than 60 patents. He has a PhD in Bio-organic Chemistry from the University of California and has graduate work in business, laws, and public health.

 

Anne Morissey

CEO & President
Ablacare

Experienced CEO, innovative strategic thinker, value creator, team builder, connector & fundraiser. Multiple exits, team transitions & global partnerships.

Anne is a passionate leader, driven to ensure positive change to the women's health ecosystem. Anne was named in the 100 Women of MedTech, 2019. Advisor to other CEO's, invited speaker including WSGR Medical Device Conference and the United Nations EWEC.

Anne Morissey

CEO & President
Ablacare

Anne Morissey

CEO & President
Ablacare

Experienced CEO, innovative strategic thinker, value creator, team builder, connector & fundraiser. Multiple exits, team transitions & global partnerships.

Anne is a passionate leader, driven to ensure positive change to the women's health ecosystem. Anne was named in the 100 Women of MedTech, 2019. Advisor to other CEO's, invited speaker including WSGR Medical Device Conference and the United Nations EWEC.

 

Juan Camilo Arjona Ferreira

Chief Medical Officer
Myovant Sciences

Juan Camilo Arjona Ferreira

Chief Medical Officer
Myovant Sciences

Juan Camilo Arjona Ferreira

Chief Medical Officer
Myovant Sciences
 

Sarah Bolt

CEO and Co-Founder
Forth

Sarah Bolt

CEO and Co-Founder
Forth

Sarah Bolt

CEO and Co-Founder
Forth
 

Wolfgang Hackl

CEO
OncogenomX

Translational oncology scientist and clinical cancer drug developer with over 20 years of experience directly contributing to pharmaceutical and scientific progress with leading companies worldwide. Proven record of achieving project and organizational objectives by building and leading high- performance teams, promoting cooperation, developing mitigation strategies, and analyzing results to ensure success. Dynamic senior leader with proactive approach to implementing efficient processes and improving staff capabilities.

Wolfgang Hackl

CEO
OncogenomX

Wolfgang Hackl

CEO
OncogenomX

Translational oncology scientist and clinical cancer drug developer with over 20 years of experience directly contributing to pharmaceutical and scientific progress with leading companies worldwide. Proven record of achieving project and organizational objectives by building and leading high- performance teams, promoting cooperation, developing mitigation strategies, and analyzing results to ensure success. Dynamic senior leader with proactive approach to implementing efficient processes and improving staff capabilities. Effective communicator, using interpersonal abilities, active listening, and observational skills to promote genuine, productive discourse. Deeply passionate about cancer research, maintaining a strong vested interest in all assigned projects to drive quality and attain large-scale goals.

 

Demonstrated success in:

  • Leading Femara global registration programs and teaming with colleagues on Aromasin registration.
  • Contributing to Proof-of-Concept (POC) for multiple targeted investigational new drugs.
  • Delivering expertise across all drug development stages: Discovery, pre-clinical research, POC, phase I to IV development.
  • Translating complex concepts into clear, relevant ideas for multilateral understanding and alignment.
  • Collaborating to create solutions, improving processes, and building strategies that enable success.

 

Demonstrated skills in:

Cancer Drug Development · Translational Clinical Oncology · NDA Filing · POC · Biomarker Development · Clinical Studies (Phase I-IV) · Medical Affairs · Wide-Ranging Subject Matter Expertise

  • · Team Building · High Performance Leadership · Problem Solving

 

 

Mary Kerr

Former CEO & Co-Founder
KaNDy Therapeutics

Mary Kerr has served as Chief Executive Officer (CEO) of NeRRe Therapeutics, a privately funded UK Biotech since 2015, and a non-executive independent director at Galapagos NV since 2016. In 2017 Mary co-founded and was CEO of KaNDy Therapeutics until the company was acquired by Bayer in September 2020 for an upfront consideration of $425 million and additional potential development, regulatory and sales milestone payments.

Mary Kerr

Former CEO & Co-Founder
KaNDy Therapeutics

Mary Kerr

Former CEO & Co-Founder
KaNDy Therapeutics

Mary Kerr has served as Chief Executive Officer (CEO) of NeRRe Therapeutics, a privately funded UK Biotech since 2015, and a non-executive independent director at Galapagos NV since 2016. In 2017 Mary co-founded and was CEO of KaNDy Therapeutics until the company was acquired by Bayer in September 2020 for an upfront consideration of $425 million and additional potential development, regulatory and sales milestone payments. Before her career in Biotech, Mary held a range of senior leadership roles at GlaxoSmithKline and heritage companies for more than 20 years, including Senior Vice President and Global Franchise leader for the Immuno-inflammation and Infectious Diseases franchise. Mary was a founding member and on the Corporate Executive team of ViiV Healthcare, where she led the European business. She has spent most of her career on the R&D commercial interface in global strategy and regional operational roles, predominantly in the specialty and orphan space. Mary gained a BSc and Ph.D. in Pharmacology at the University of Bradford, did post-doctoral research at the Michigan Cancer Foundation in Detroit, and has an MBA from the University of Kingston.

DOWNLOAD AGENDA

The 2022 Women's Health Innovation Summit Europe agenda!

Sessions included:

  • Innovation and Investment in Europe: Driving Growth in Women’s Health

  • Hormonal Health: The Next Frontier

  • Engaging Employers to Increase Women’s Access to Healthcare

Our agenda provides all the information from our previous event, view it today!

Download the 2022 WHIS EU Agenda

REGISTRATION

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Monday, July 25, 2022 to Tuesday, September 26, 2023
NPO/Charity Rate
€499
Friday, August 5, 2022 to Friday, November 4, 2022
Emerging - Under 5mil Rev
€ 499
Pre-Launch (Register before the 4th Nov and save €400)
Friday, August 5, 2022 to Friday, November 4, 2022
Emerging - Under 10mil Rev
€ 699
Pre-Launch (Register before the 4th Nov and save €400)
Friday, August 5, 2022 to Friday, November 4, 2022
Industry
€ 1,299
Pre-Launch (Register before the 4th Nov and save €800)
Friday, August 5, 2022 to Friday, November 4, 2022
Service Providers
€ 1,799
Pre-Launch (Register before the 4th Nov and save €800)
Preparing registration...

Venue Description

Venue

Congress Center Basel Messepl. 21, 4058 Basel, Switzerland

The Congress Center Basel is the largest congress center in Switzerland in terms of area. Look forward to comfortable furnishings and the latest technology that meets even the highest demands.

Partner With Us

Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

To discuss your objectives and partnership opportunities please contact [email protected]

Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]

Returning Safely Measures

Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.

All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.

Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.

Download the Kisaco Research Returning Safely Measures 

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Kisaco Research
Registered office address: 41a Maltby Street, London, SE1 3PA
+44 (0)20 3696 2920 | [email protected]
Place of registration: London, United Kingdom
Company number: 09316521

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Other events you might be interested in:

Women's Health Innovation Series: Women's Healthy Aging Summit

Women's Health Innovation Summit 2023

Reproductive Health Innovation Summit